EMEA-002886-PIP01-20-M01
Key facts
| Active substance |
Human, recombinant, non-fucosylated IgG1k monoclonal antibody targeting OX-40 receptor on activated T cells (AMG 451)
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0168/2022
|
| PIP number |
EMEA-002886-PIP01-20-M01
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of atopic dermatitis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Amgen Europe B.V.
E-mail: medinfointernational@amgen.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|